BioCardia Inc (BioCardia) is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, an autologous minimally processed bone marrow cells, an allogeneic off-the-shelf mesenchymal stem cell product candidate for ischemic systolic heart failure. Its CardiAMP cell therapy system comprises cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. BioCardia also offers catheters for use in the delivery of therapeutic agents directly to the heart and guiding catheters for use in peripheral and coronary vasculature and chambers of the heart. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company BioCardia Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
BioCardia Inc Company Overview
BioCardia Inc Company Snapshot
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
BioCardia Inc – Pipeline Analysis Overview
BioCardia Inc - Key Facts
BioCardia Inc - Major Products and Services
BioCardia Inc Pipeline Products by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status
Helix Transendocardial Delivery System Product Overview
Helix Transendocardial Delivery System Clinical Trial
BioCardia Inc - Key Competitors
BioCardia Inc - Key Employees
BioCardia Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
BioCardia Inc, Recent Developments
Jul 15, 2021: BioCardia announces Japanese patent on imaging system for targeting cardiac therapies
Apr 14, 2020: BioCardia announces litigation financing in the case captioned Boston Scientific
Mar 12, 2020: Biocardia announces timing for Prespecified Data Safety Monitoring Board Report on Pivotal Cardiamp Heart Failure Trial
Jan 14, 2020: BioCardia announces FDA clearance of Morph DNA Deflectable Guide Catheter
Jan 08, 2020: BioCardia announces new U.S. patent covering CardiAMP cell therapy and issuance of two Asian patents covering Radial Artery approach for Cardiac Cell and Gene Therapy Delivery
Oct 08, 2019: BioCardia receives CE Mark renewal for Helix Biotherapeutic Delivery Catheter And Morph Guide Catheter through May 2024
Oct 01, 2019: BioCardia Initiates Commercial Release of AVANCE Steerable Introducer Designed to Enhance Physician Control for Complex Cardiac Procedures
Sep 16, 2019: BioCardia announces positive DSMB recommendation to continue phase 3 pivotal CardiAMP heart failure study as planned
Jun 12, 2019: BioCardia announces issuance of Chinese patent for image-guided biotherapeutic delivery
May 23, 2019: Acute Myocardial Infarction patients treated early with cell therapy delivered with BioCardia's HElix Endocardial Delivery System improved in ejection fraction and NYHA class
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
BioCardia Inc Pipeline Products and Ongoing Clinical Trials Overview
BioCardia Inc Pipeline Products by Equipment Type
BioCardia Inc Pipeline Products by Indication
BioCardia Inc Ongoing Clinical Trials by Trial Status
BioCardia Inc, Key Facts
BioCardia Inc, Major Products and Services
BioCardia Inc Number of Pipeline Products by Development Stage
BioCardia Inc Pipeline Products Summary by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status
BioCardia Inc Ongoing Clinical Trials Summary
CardiALLO - Ischemic Heart Failure - Product Status
CardiAMP - Chronic Myocardial Ischemia - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients with Refractory Angina Pectoris and Chronic Myocardial Ischemia: CardiAMP CMI Trial
CardiAMP - Heart Failure - Product Status
CardiAMP - Heart Failure - Product Description
CardiAMP - Heart Failure - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure: CardiAMP Heart Failure Trial
CardiAMP - Post Acute Infarction - Product Status
CardiAMP - Post Acute Infarction - Product Description
Fusion Imaging System - Product Status
Fusion Imaging System - Product Description
Helix Transendocardial Delivery System - Product Status
Helix Transendocardial Delivery System - Product Description
Helix Transendocardial Delivery System - A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand Automated Process, and Injected in Patients with an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% after PTCA and Stent(s) Implantation Versus Standard of Care
Helix Transendocardial Delivery System - Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)
Helix Transendocardial Delivery System - Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure: CardiAMP Heart Failure Trial
BioCardia Inc, Key Employees
BioCardia Inc, Subsidiaries
Glossary
List of Figures
BioCardia Inc Pipeline Products by Equipment Type
BioCardia Inc Pipeline Products by Development Stage
BioCardia Inc Ongoing Clinical Trials by Trial Status